Viatris

Viatris is a pharmaceutical company based in Canonsburg, Penn. It formed in 2020 through a merger between Mylan and Upjohn, Pfizer’s off-patent medicine division. The company creates brand and generic drugs for infectious diseases and non-communicable diseases. Its portfolio of medications include Viagra, Xanax, and Lipitor. Viatris beat analyst expectations with reported sales of $4.4 billion in its first quarterly earnings report. Lipitor, which is used to treat high cholesterol, and Norvasc, which is used to treat high blood pressure, led in sales with $464.6 million and $227.7 million, respectively. The company employs around 45,000 people worldwide and has 50 manufacturing plants that produce oral solid doses, injectables, and active pharmaceutical ingredients.

Company Information

As of 5/23/2022
Country
U.S.
Headquarters
Canonsburg, Pa.
Industry
Pharmaceuticals
CEO
Michael Goettler
Company Type
Public
Ticker
VTRS
Revenues ($M)
$17,886.3
Profits ($M)
$-1,269.1
Market Value ($M)
$13,160.2
Employees
37,000
Market value as of March 31, 2022.

Key Financials (Last Fiscal Year)

$ millions
% change
Revenues ($M)
$17,886.3
49.7%
Profits ($M)
$-1,269.1
-
Assets ($M)
$54,842.8
-
Total Stockholder Equity ($M)
$20,492.7
-

Profit Ratios

Profit as % of Revenues
-7.1%
Profits as % of Assets
-2.3%
Profits as % of Stockholder Equity
-6.2%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)
-1
EPS % Change (from 2020)
-
EPS % Change (5 year annual rate)
-
EPS % Change (10 year annual rate)
-

Total Return

Total Return to Investors (2021)
-26.1%
Total Return to Investors (5 year, annualized)
-
Total Return to Investors (10 year, annualized)
-

Change the World

Impact Segment
-
Sector
Health Care
Prior Year Rank
-
Lists ranking Viatris
RANK204
Fortune 500 - 2022This year’s Fortune 500 marks the 68th running of ...READ MORE